JP2017503763A - Ｇｃｃ発現細胞を撮像するための化合物及び組成物 - Google Patents

Ｇｃｃ発現細胞を撮像するための化合物及び組成物 Download PDF

Info

Publication number
JP2017503763A
JP2017503763A JP2016536174A JP2016536174A JP2017503763A JP 2017503763 A JP2017503763 A JP 2017503763A JP 2016536174 A JP2016536174 A JP 2016536174A JP 2016536174 A JP2016536174 A JP 2016536174A JP 2017503763 A JP2017503763 A JP 2017503763A
Authority
JP
Japan
Prior art keywords
compound
gcc
seq
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503763A5 (enExample
Inventor
ドナ シーベット，
ドナ シーベット，
スワプニル ラウト，
スワプニル ラウト，
マイケル ケー． シュルツ，
マイケル ケー． シュルツ，
ジェフリー ピー． ノーレンバーグ，
ジェフリー ピー． ノーレンバーグ，
タマラ アンダーソン ダニエルズ，
タマラ アンダーソン ダニエルズ，
ジョン ウィリアム ホッピン，
ジョン ウィリアム ホッピン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
UNM Rainforest Innovations
Original Assignee
Millennium Pharmaceuticals Inc
STC UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc, STC UNM filed Critical Millennium Pharmaceuticals Inc
Publication of JP2017503763A publication Critical patent/JP2017503763A/ja
Publication of JP2017503763A5 publication Critical patent/JP2017503763A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
JP2016536174A 2013-12-03 2014-12-03 Ｇｃｃ発現細胞を撮像するための化合物及び組成物 Pending JP2017503763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911323P 2013-12-03 2013-12-03
US61/911,323 2013-12-03
PCT/US2014/068431 WO2015084996A1 (en) 2013-12-03 2014-12-03 Compounds and compositions for imaging gcc-expressing cells

Publications (2)

Publication Number Publication Date
JP2017503763A true JP2017503763A (ja) 2017-02-02
JP2017503763A5 JP2017503763A5 (enExample) 2018-01-18

Family

ID=53274087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536174A Pending JP2017503763A (ja) 2013-12-03 2014-12-03 Ｇｃｃ発現細胞を撮像するための化合物及び組成物

Country Status (4)

Country Link
US (1) US20160303258A1 (enExample)
EP (1) EP3077407A4 (enExample)
JP (1) JP2017503763A (enExample)
WO (1) WO2015084996A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511462A (ja) * 2016-02-05 2019-04-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｃｃ標的化抗体−薬物コンジュゲート
WO2021033530A1 (ja) * 2019-08-21 2021-02-25 日本メジフィジックス株式会社 放射性金属錯体の製造方法
WO2021075544A1 (ja) * 2019-10-18 2021-04-22 日本メジフィジックス株式会社 Ｒｉ標識されたヒト化抗体
JP2021076598A (ja) * 2019-10-31 2021-05-20 キヤノンメディカルシステムズ株式会社 解析装置および解析プログラム
WO2022225006A1 (ja) * 2021-04-21 2022-10-27 日本メジフィジックス株式会社 β線を放出する核種で標識されたヒト化抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050242A1 (en) 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
AU2017358509A1 (en) * 2016-11-11 2019-05-09 Bayer Aktiengesellschaft Method for sampling fluid streams for monitoring contaminants in a continuous flow

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524323A (ja) * 2001-03-02 2004-08-12 アメルシャム・パブリック・リミテッド・カンパニー 結腸直腸癌診断のためのテトラデンテートペプチド−キレートコンジュゲート
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
EP1599165A4 (en) * 2003-02-10 2010-09-08 Univ Jefferson THE USE OF GCC LIGANDS
WO2008026051A2 (en) * 2006-08-29 2008-03-06 Ge Healthcare Limited 68ga-labelling of a free and macromolecule conjugated macrocyclic chelator at ambient temperature
US8545809B2 (en) * 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
JP5789821B2 (ja) * 2009-12-04 2015-10-07 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． タンパク質、ペプチドおよび他の分子の改善されたｆ−１８標識化のための方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524323A (ja) * 2001-03-02 2004-08-12 アメルシャム・パブリック・リミテッド・カンパニー 結腸直腸癌診断のためのテトラデンテートペプチド−キレートコンジュゲート
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511462A (ja) * 2016-02-05 2019-04-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｃｃ標的化抗体−薬物コンジュゲート
WO2021033530A1 (ja) * 2019-08-21 2021-02-25 日本メジフィジックス株式会社 放射性金属錯体の製造方法
JPWO2021033530A1 (enExample) * 2019-08-21 2021-02-25
JP7744828B2 (ja) 2019-08-21 2025-09-26 日本メジフィジックス株式会社 放射性金属錯体の製造方法
JP7036996B2 (ja) 2019-10-18 2022-03-15 日本メジフィジックス株式会社 Ｒｉ標識されたヒト化抗体
JPWO2021075544A1 (ja) * 2019-10-18 2021-11-04 日本メジフィジックス株式会社 Ｒｉ標識されたヒト化抗体
JP2022088398A (ja) * 2019-10-18 2022-06-14 日本メジフィジックス株式会社 Ｒｉ標識されたヒト化抗体
US11369701B2 (en) 2019-10-18 2022-06-28 Nihon Medi-Physics Co., Ltd. Ri-labeled humanized antibody
JP7679326B2 (ja) 2019-10-18 2025-05-19 日本メジフィジックス株式会社 Ｒｉ標識されたヒト化抗体
WO2021075544A1 (ja) * 2019-10-18 2021-04-22 日本メジフィジックス株式会社 Ｒｉ標識されたヒト化抗体
JP2021076598A (ja) * 2019-10-31 2021-05-20 キヤノンメディカルシステムズ株式会社 解析装置および解析プログラム
JP7589935B2 (ja) 2019-10-31 2024-11-26 キヤノンメディカルシステムズ株式会社 解析装置および解析プログラム
WO2022225006A1 (ja) * 2021-04-21 2022-10-27 日本メジフィジックス株式会社 β線を放出する核種で標識されたヒト化抗体

Also Published As

Publication number Publication date
US20160303258A1 (en) 2016-10-20
EP3077407A4 (en) 2017-07-19
EP3077407A1 (en) 2016-10-12
WO2015084996A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
JP2017503763A (ja) Ｇｃｃ発現細胞を撮像するための化合物及び組成物
JP6953444B2 (ja) Ｐｅｔイメージング用免疫修飾因子
US20090297439A1 (en) Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
EP2795317B1 (en) Composition for use in a method for cancer selection
EP2127683A1 (en) Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
US20240342322A1 (en) Netrin-1 detection, companion test and therapy based on radiations
JP2017214308A (ja) 放射性医薬組成物、及び、放射能標識抗体のスクリーニング方法
Baum et al. Third theranostics world congress on gallium-68 and PRRT: abstracts
JP2021508335A (ja) 癌診断における放射性標識プロガストリン
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
Ku Theranostic Implications of Molecular Imaging in Cancer
CA3234495A1 (en) Combination therapy of radionuclide complex
Korsen Molecular Imaging and Radioimmunotherapy Targeting Delta-Like Ligand 3 in Neuroendocrine Prostate Cancer
US20250387523A1 (en) Combination therapy of radionuclide complex
Mishra et al. GALLIUM-68-LABELED PEPTIDE PET QUANTIFIES TUMOR EXPOSURE OF PD-L1
Buck et al. Preclinical and clinical tumor imaging with SPECT/CT and PET/CT
MOROZ PRECLINICAL TESTING OF NEW MODALITIES FOR PET VISUALIZATION AND TREATMENT OF RAS-DRIVEN CANCERS
HEAD RADIOIMMUNO RADIOIMMUNO

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190422